NASDAQ:IMCR Immunocore Q2 2026 Earnings Report $33.42 -0.09 (-0.27%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$33.41 -0.01 (-0.03%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunocore EPS ResultsActual EPSN/AConsensus EPS -$0.01Beat/MissN/AOne Year Ago EPSN/AImmunocore Revenue ResultsActual RevenueN/AExpected Revenue$146.69 millionBeat/MissN/AYoY Revenue GrowthN/AImmunocore Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time2:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Immunocore Earnings HeadlinesImmunocore to report second quarter 2026 financial results and host call on August 6, 20261 hour ago | globenewswire.comImmunocore (NASDAQ:IMCR) Stock Rating Lowered by Wall Street ZenJuly 28 at 1:06 AM | americanbankingnews.comPass by August 7… or wait until 2027?Right now, your phone is recording exactly where you are. It does this roughly every two minutes. Precise coordinates. Stored on corporate servers. For years. Your church. Your doctor. Your home. Your habits. The most complete map of a human life ever assembled… and for years, the government could simply ask for it. On June 29th, the Supreme Court said: no more. In a landmark 6–3 ruling, your digital life now carries the same constitutional protection as your home. The Founders would be proud. But they'd also notice what's still exposed… Your money. That’s why this ruling has actually opened the door to a tremendous opportunity. Because while the courts just ruled on our freedoms, technology needs to enforce the ruling.July 30 at 1:00 AM | Crypto 101 Media (Ad)Immunocore (NASDAQ:IMCR) Raised to Buy at Wall Street ZenJuly 20, 2026 | americanbankingnews.comIs Immunocore Holdings (IMCR) Undervalued After Its Recent Share Price Rebound?July 9, 2026 | finance.yahoo.comImmunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR PlatformJune 24, 2026 | seekingalpha.comSee More Immunocore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email. Email Address About ImmunocoreImmunocore (NASDAQ:IMCR) plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need. The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma. Beyond this, Immunocore’s pipeline includes multiple additional ImmTAC candidates in various stages of clinical evaluation across solid tumor indications such as colorectal, lung and other metastatic cancers. The firm also pursues collaborations with major biopharmaceutical partners to expand the reach and application of its TCR technology, notably with Genentech and Fosun Pharma. Headquartered in Oxford, England, with research and development facilities in Philadelphia, Pennsylvania, Immunocore leverages a global infrastructure to support its clinical trials and manufacturing efforts. Founded in 2008, the company is led by Chief Executive Officer Dr. Bahija Jallal, under whose direction Immunocore has advanced its first‐in‐class therapies from discovery through late‐stage clinical development. With a commitment to innovation in immune‐based medicine, Immunocore continues to explore new targets and indications that may benefit from the specificity and potency of its TCR‐based platform.View Immunocore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why SK hynix Could Be the Best AI Chip Stock to Buy NowWhy Bloom Energy May Be the Most Important AI Infrastructure StockAlphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?Seagate Technology Stock Surges as Earnings Beat Silences AI DoubtersUnitedHealth Just Gave Wall Street a Clearer Turnaround SignalCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel Supply Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
